Outcomes of hematologic malignancy patients with SARS-CoV-2 breakthrough infections after tixagevimab-cilgavimab during community transmission of monoclonal antibody resistant variants.

Mini Kamboj Justin C Laracy Shauna Usiak N Esther Babady Judy Yan Susan K Seo

J Infect

Infectious Disease Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Medicine, Weill Cornell Medical College, New York, NY, USA.

Published: September 2023

Download full-text PDF	Source
http://dx.doi.org/10.1016/j.jinf.2023.06.024	DOI Listing

Publication Analysis

Top Keywords

outcomes hematologic

hematologic malignancy

malignancy patients

patients sars-cov-2

sars-cov-2 breakthrough

breakthrough infections

infections tixagevimab-cilgavimab

tixagevimab-cilgavimab community

community transmission

transmission monoclonal

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!